PDGFRB and neoplasm: It has been reported that imatinib, a tyrosine kinase inhibitor of PDGFRβ, induced apoptosis of tumour-associated PDGFRβ1 pericytes and impaired growth of lymphoma, indicating that pericytes may represent a novel target for lymphoma therapy (42).